US3577544A - Methods for producing muscle relaxant and cns-depressant effects with 3-amino-4-phenyl furazan and composition therefor - Google Patents

Methods for producing muscle relaxant and cns-depressant effects with 3-amino-4-phenyl furazan and composition therefor Download PDF

Info

Publication number
US3577544A
US3577544A US702550A US3577544DA US3577544A US 3577544 A US3577544 A US 3577544A US 702550 A US702550 A US 702550A US 3577544D A US3577544D A US 3577544DA US 3577544 A US3577544 A US 3577544A
Authority
US
United States
Prior art keywords
furazan
amino
phenyl
cns
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US702550A
Other languages
English (en)
Inventor
Claude Lehmann
Ernst Renk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Corp
Original Assignee
Geigy Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geigy Chemical Corp filed Critical Geigy Chemical Corp
Application granted granted Critical
Publication of US3577544A publication Critical patent/US3577544A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Definitions

  • the present invention concerns a new method and a new agent for the tretament of pathologically increased muscle tone in mammals.
  • 3-amino-4-phenylfurazan is a good central muscle relaxant having a high therapeutic index.
  • the active substance can be used, e.g. to relieve pathologically increased muscle tone caused by rheumatic diseases, fibrositis, bursitis, myositis, torticollis, spondylitis or disc lesions.
  • the muscle relaxant effect is ascertained pharmacologically by various methods.
  • a characteristic of the central muscle relaxants is the abolition of the pinna reflex after administration of fairly small quantities of active ingredient, whereas the corneal reflex can only be abolished after much higher dosage.
  • the reflexes are determined in white mice weighing 18-25 g.
  • the pinna reflex and the corneal reflex are tested by stroking the external auditory meatus or touching the cornea with a nylon brush.
  • the dosage is determined at which the pinna reflex and the corneal reflex are abolished in 50% of the animals.
  • the mice are not fed for 12 hours before the beginning of the test.
  • the test substance is administered by mouth 1 hour before the test.
  • the E.D. is ascertained by interpolation of the probability graph (Schleicher and Schiill No. 298 /2).
  • FLEXOR REFLEX The contractions of the tibialis anterior muscle of the left hind leg are recorded isotonically after Submaximal electrical stimulation of the central section of the severed tibial nerve.
  • Submaximal stimulation is effected with single rectangular current impulses (Grass stimulator, dura tion of stimulation: 2 m. sec., voltage 0.5-5.0 v.). The interval between two stimulations is 10 seconds.
  • the maximum change in amplitude is determined in percent "ice (c) Determination of the anticonvulsant effect by means of electroshock in the rat (partial suppression).
  • Procedure Male white rats weighing -150 g. are used for the test. The electrodes are applied to the external ears. An alternating current of 50 c./ s. of 100 v. is used for the electroshock and the stimulation lasts 0.63 second. The test substance is administered by mouth 1 hour before the electroshock. The dose which prevents tonic convulsions in the hind legs in 50% of the animals is ascertained by interpolation on the probability graph (Schleicher and Schiill No. 298 /2 (E.D.
  • the acute toxicity of the test compound is determined by a single administration by mouth in male and female mice. The observation period is 8 days.
  • the L.D. is determined by interpolation on the probability graph (Schleicher and Schiill No. 298 /2 Result: Acute L.D. O mg./kg. p.o.
  • the acute toxicity is also tested in male and female rabbits weighing 1.5-2.0 kg.
  • the test compound is administered i.e. in 5% solution in 100% propylene glycol.
  • a speed of injection is 1 ml. in 30 seconds.
  • the daily dosages of the active substance vary between 45 and 6000 mg. for adult patients of normal bodyweight. For children, dosages reduced according to their weight are administered. Suitable dosage units such as drages (sugar coated tablets), tablets, suppositories and ampoules, preferably contain 15-1000 mg. of the compound.
  • Dosage units for oral administration preferably contain between 60-90% of 3-amino-4-phenyl-furazan as active ingredient.
  • the active substance is combined, e.g. with solid, pulverulent carriers such as lactose, saccharose, sorbitol, mannitol, maize starch, potato starch, amylopectin, talcum, also laminaria powder or citrus pulp powder, optionally with the addition of lubricants and binders such as highly dispersed silicic acid, magnesium or calcium stearate, stearic acid, glycerin or polyethylene glycols or gelatin or cellulose derivatives such as ethyl cellulose and sodium salt of carboxymethyl cellulose.
  • solid, pulverulent carriers such as lactose, saccharose, sorbitol, mannitol, maize starch, potato starch, amylopectin, talcum, also laminaria powder or citrus pulp powder, optionally with the addition of lubric
  • Drage cores are then coated, e.g. with concentrated sugar solutions which can also contain, e.g. gum arabic, talcum and/or titanium dioxide, or with a lacquer dissolved in easily volatile organic solvents or mixtures of solvents, e.g. shellac.
  • Dyestuffs can be added to these coatings, e.g. to distinguish between varying dosages of active substance.
  • suitable dosage units for oral administration are hard gelatine capsules as well as soft capsules made of gelatine and a softener such as glycerin.
  • the hard capsules preferably contain the active substance in the form of a granulate in admixture with diluents such as lactose, saccharose or maize starch, and/or lubricants such as talcum or magnesium stearate and, optionally, stabilisers such as sodium metabisulphite (Na S O or ascorbic acid.
  • the active substance is preferably dissolved or suspended in suitable liquids such as liquid polyethylene glycols or oils, to which stabilisers can also be added.
  • Dosage units which are also suitable for oral administration are, e.g. pastilles prepared with the usual additives.
  • dosage units for rectal administration are suppositories which consist of a combination of S-amino- 4-phenylfurazan with a suppository foundation, e.g. natural or synthetic triglycerides, or also gelatine rectal capsules which contain, e.'g. a combination of the active substance with polyethylene glycols or oils.
  • Dosage units for parenteral administration advantageously contain 110% of active substance, water and a solubility promoter or emulsifier.
  • the following compounds can be used as solubility promoters or emulsifiers: propylene glycol, sodium benzoate or the sodium salt of a hydroxybenzoic acid, water soluble salts of bile acids such as sodium dehydrocholate, morpholine desoxycholate, ethanolamine cholate, inositol phosphatide preparations and lecithin preparations having a poor oil content, optionally together with partial glycerides of higher fatty acids such as monoor di-olein, and/or their polyoxyethylene derivatives.
  • the present invention relates to methods of treating convulsions, muscular stiflfness and mental disorders in mammals and to therapeutic composition for producing anticonvulsive, muscle-relaxing, and CNS-depressing effects comprising a pharmaceutical carrier and a therapeutically effective amount of 3-amino-4-phenyl furazan in dosage unit form acceptable for internal administration.
  • EXAMPLE 1 To produce 100,000 tablets, each of which contains 500 mg. of active substance, 50.000 kg. of 3-amino-4-phenyl furazan are mixed with 2.000 kg. of dried potato starch. The mass obtained is moistened with 1.200 kg. of stearic acid in 4 litres of ethanol and the whole is mixed for minutes. 1.200 kg. of gelatine in 16 litres of distilled water are then added and the mass is kneeded for 20 minutes. As soon as it is sufficiently moist, it is granulated through a sieve mesh/sq. cm.) and dried. The dried granulate is again sieved (60 mesh/sq. cm.) and is 4 then mixed for 1 hour with 4.000 kg. of potato starch, 1.200 kg. of talcum and 0.400 kg. of sodium carboxymethyl cellulose. The mass obtained is pressed into tablets, each of which weighs 600 mg.
  • Example 2 To produce 100,000 drages, each of which contains 500 mg. of 3-amino-4-phenyl-furazan as active substance, 50.000 kg. of active substance are mixed with 3.700 kg. of lactose and 1.000 kg. of highly dispersed kieselguhr. The mixture is moistened with a granulating liquid heated to 50 C. consisting of 2.000 kg. of gelatine, 2.000 kg. of glycerin and 1.5 litres of water. The moist mixture is granulated through a suitable sieve (e.g. sieve III, Ph. Helv. V.). The granulate is then dried for 8 hours in a drying, oven at 40-50 C. or in a fluidised-bed drier for about 40 minutes at 40 C.
  • a suitable sieve e.g. sieve III, Ph. Helv. V.
  • a suitable sieve e.g. sieve III-IIIa, Ph. Helv. V.
  • the granulate is. then mixed with 3.000 kg. of talcum and 3.000 kg. of maize starch and 300' g. of magnesium stearate and the mixture is pressed into 1,000,000 drage cores each of which weights 6 50 mg.
  • Example 3 To produce 1,000 capsules each containing 500 mg. of active substance, 500.0 g. of 3-amino-4-phenyl-furazan are mixed with 25.0 g. of talcum and 10.0 g. of magnesium stearate and the mixture is sieved through a sieve (e.g. sieve IV, Ph. Helv. V) whereupon it is evenly filled into capsules of size 0.
  • a sieve e.g. sieve IV, Ph. Helv. V
  • Example 4 Suppositories are prepared by mixing 750 g. of 3- amino-4-pheny1 furazan with 2.250 kg. of adeps solidus and then forming 1000 suppositories of 3.0 g. of each containing 750 mg. of 3-amino-4-phenyl furazan.
  • a therapeutic composition for producing a muscle relaxing or central nervous system depressant effect comprising a pharmaceutical carrier and a therapeutically effective amount of 3-amino-4-phenyl furazan in a unit dosage form selected from the group consisting of a drage, tablet, capsule, pastille, suppository and ampoule.
  • the method of producing a muscle-relaxing or a central nervous system depressant effect in a mammal comprising administering to said mammal an effective amount of 3-amino-4-phenyl furazan.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
US702550A 1968-01-26 1968-02-02 Methods for producing muscle relaxant and cns-depressant effects with 3-amino-4-phenyl furazan and composition therefor Expired - Lifetime US3577544A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH125068 1968-01-26

Publications (1)

Publication Number Publication Date
US3577544A true US3577544A (en) 1971-05-04

Family

ID=4205989

Family Applications (1)

Application Number Title Priority Date Filing Date
US702550A Expired - Lifetime US3577544A (en) 1968-01-26 1968-02-02 Methods for producing muscle relaxant and cns-depressant effects with 3-amino-4-phenyl furazan and composition therefor

Country Status (7)

Country Link
US (1) US3577544A (en))
BE (1) BE727363A (en))
DE (1) DE1903569A1 (en))
FR (1) FR2000802A1 (en))
GB (1) GB1254893A (en))
IL (1) IL31486A (en))
NL (1) NL6900839A (en))

Also Published As

Publication number Publication date
GB1254893A (en) 1971-11-24
DE1903569A1 (de) 1969-08-28
FR2000802A1 (en)) 1969-09-12
NL6900839A (en)) 1969-07-29
BE727363A (en)) 1969-07-24
IL31486A0 (en) 1969-03-27
IL31486A (en) 1972-07-26

Similar Documents

Publication Publication Date Title
US4362731A (en) Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
FI82934C (fi) Foerfarande foer framstaellning av farmakologiskt verksamt 8-klor-6,11-dihydro-11-(4-piperidyliden)-5h benzo/5,6/cyklohepta/1,2-b/pyridin.
US5962494A (en) Methods for treating behavioral and other disorders using optically pure R(+) ondansetron
US5153191A (en) Cholecystokinin antagonists useful for treating depression
AU579028B2 (en) Anticonvulsant compositions and method
US3001910A (en) Anorexigenic propiophenones
US3577544A (en) Methods for producing muscle relaxant and cns-depressant effects with 3-amino-4-phenyl furazan and composition therefor
IE60267B1 (en) Centrally-acting muscle relaxants
US2817623A (en) Tabernanthine, ibogaine containing analgesic compositions
KR100352898B1 (ko) 새로운3-벤조일-3,7-디아자바이사이클로[3,3,1]노난-화합물을함유하는약제
US3988461A (en) Pharmaceutical composition for the treatment of Parkinson's disease
US3867529A (en) Tranquilizing and anti-anxiety pharmaceutical compositions
US3629441A (en) Compositions containing physiologically active kawa compounds process of making same and method of using same in therapy
US4189478A (en) Medicinal composition and its use as antidepressive agent
AU2254692A (en) Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron
Oosterlinck et al. Preliminary clinical experience with meptazinol, a new analgesic
US3462534A (en) Production of an antidepressant effect with esters of gallic acid
US3629418A (en) Process for producing an anti-depressant effect with piperazine quinolines
Rosenberg et al. Nikethamide, nicotinamide and some related compounds in anticholinesterase poisoning
JPH0232020A (ja) モルフィン鎮痛治療における耐性発現の抑制方法および薬剤
US3337408A (en) Method of effecting analgesia
US1166208A (en) Physiologically-active base.
JPS58219119A (ja) 鎮痛作用を有する医薬
US3507960A (en) Anti-anxiety compositions and a method of producing anti - anxiety activity with combinations of amobarbital and trifluoperazine
US3126319A (en) Method for the potentiation of anti-